Table 1 Characteristics of included studies
Trial | Types of Study | Population | N | Ivabradine regimen | Non-Ivabradine Group | Endpoint | Time (days) |
|---|---|---|---|---|---|---|---|
Priti, et al. [8] | RCT | Acute Inferior wall STEMI | 464 | 2.5–7.5 mg bid, PO | Metoprolol | MACE | 30 |
Barilla, et al. [9] | RCT | CS complicating STEMI | 58 | 2.5–7.5 mg bid, PO/NGT | Standard treatment | NT-proBNP | 180 |
Rezq, et al. [10] | RCT | Acute Anterior wall STEMI | 670 | 5 mg bid, PO | Bisoprolol | MACE | 365 |
Fasullo, et al. [11] | RCT | Acute Anterior wall STEMI | 155 | 2.5–7.5 mg bid, PO | Metoprolol Succinate | LV remodeling | 60 |
Steg, et al. [12] | RCT | Acute STEMI | 124 | 5 mg, IV | Placebo | Heart Rate | 120 |
Xu, et al. [13] | RCT | Acute STEMI | 66 | 2.5–7.5 mg bid, PO | Metoprolol | LV remodeling | 180 |